Bibi Fatemeh Haghiralsadat (Fateme Haghiralsadat)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 8

Top Topics

Hyaluronic Acid

Top Venues

Nanomedicine (London, England)

Artificial cells, nanomedicine, and biotechnology

Chemical biology & drug design

This page only lists publications with an associated author ORCID identifier.

Publications

Maryamsadat Shahidi, Omid Abazari, Parisa Dayati, Javad Zavar Reza, Mohammad Hossein Modarressi, Davood Tofighi, Bibi Fatemeh Haghiralsadat, Fatemeh Oroojalian
Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer. Nanomedicine (London, England) (2023)
Maryamsadat Shahidi, Omid Abazari, Parisa Dayati, Javad Zavar Reza, Mohammad Hossein Modarressi, Davood Tofighi, Bibi Fatemeh Haghiralsadat, Fatemeh Oroojalian
Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer. Nanomedicine (London, England) 18 (3) (2023)
Maryamsadat Shahidi, Omid Abazari, Parisa Dayati, Javad Zavar Reza, Mohammad Hossein Modarressi, Davood Tofighi, Bibi Fatemeh Haghiralsadat, Fatemeh Oroojalian
Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer. Nanomedicine (London, England) 18 (3) (2023)
Maryamsadat Shahidi, Omid Abazari, Parisa Dayati, Javad Zavar Reza, Mohammad Hossein Modarressi, Davood Tofighi, Bibi Fatemeh Haghiralsadat, Fatemeh Oroojalian
Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer. Nanomedicine (London, England) 18 (3) (2023)
Maryamsadat Shahidi, Omid Abazari, Parisa Dayati, Javad Zavar Reza, Mohammad Hossein Modarressi, Davood Tofighi, Bibi Fatemeh Haghiralsadat, Fatemeh Oroojalian
Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer. Nanomedicine (London, England) 18 (3) (2023)
Bibi Fatemeh Haghiralsadat, Ghasem Amoabediny, Samira Naderinezhad, Tymour Forouzanfar, Marco N Helder, Behrouz Zandieh-Doulabi
Preparation of PEGylated cationic nanoliposome-siRNA complexes for cancer therapy. Artificial cells, nanomedicine, and biotechnology 46 (sup1) (2018)
Mahdie Hemati, Bibi Fatemeh Haghiralsadat, Fatemeh Yazdian, Farzaneh Jafari, Ali Moradi, Zahra Malekpour-Dehkordi
Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy. Artificial cells, nanomedicine, and biotechnology 47 (1) (2018)
Bibi Fatemeh Haghiralsadat, Ghasem Amoabediny, Mohammad Hasan Sheikhha, Behrouz Zandieh-Doulabi, Samira Naderinezhad, Marco N Helder, Tymour Forouzanfar
New liposomal doxorubicin nanoformulation for osteosarcoma: Drug release kinetic study based on thermo and pH sensitivity. Chemical biology & drug design 90 (3) (2017)